SGLT2 Inhibitors Show No Significant Serious UTI Excess
This trial-level meta-analysis reassures pharmacists that SGLT2 inhibitor urinary safety differs meaningfully from the well-established genital infection risk.
📅 Journal publication: Aug 7, 2026·Last updated: Aug 8, 2026
SGLT2 inhibitors show no significant rise in UTI risk.
The risk of urinary tract infections (UTIs) with SGLT2 inhibitors is unclear despite their common use for type 2 diabetes, heart failure, and chronic kidney disease. SGLT2 inhibitors did not show a statistically significant increase in any UTI (RR 1.08, P = 0.060) or serious/complicated UTI (RR 0.99, P = 0.960). These results indicate no significant rise in UTIs, differentiating between lower-grade urinary events and more severe infections, unlike the known risk of genital infections. SGLT2 inhibitors do not significantly increase UTI risk, distinguishing them from risks of genital infections.
📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.
Free account, no credit card. Includes 1 full deep analysis every month.
Authors:Matteucci A, Di Fusco SA, Bonanni M, Castello L, Aquilani S, Fedele S, Nardi F, Colivicchi F
Citation:Matteucci A, Di Fusco SA, Bonanni M, et al. Are SGLT2 inhibitors really associated with increased urinary tract infection risk? A trial-level meta-analysis across type 2 diabetes, heart failure, and chronic kidney disease. Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences. 2026;34(2). doi:10.1007/s40199-026-00637-7